Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease.

Details

Ressource 1Download: 2021-SciRep Rackayova.pdf (2015.11 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_9A9CF9B0223E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Probiotics improve the neurometabolic profile of rats with chronic cholestatic liver disease.
Journal
Scientific reports
Author(s)
Rackayová V., Flatt E., Braissant O., Grosse J., Capobianco D., Mastromarino P., McMillin M., DeMorrow S., McLin V.A., Cudalbu C.
ISSN
2045-2322 (Electronic)
ISSN-L
2045-2322
Publication state
Published
Issued date
26/01/2021
Peer-reviewed
Oui
Volume
11
Number
1
Pages
2269
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Chronic liver disease leads to neuropsychiatric complications called hepatic encephalopathy (HE). Current treatments have some limitations in their efficacy and tolerability, emphasizing the need for alternative therapies. Modulation of gut bacterial flora using probiotics is emerging as a therapeutic alternative. However, knowledge about how probiotics influence brain metabolite changes during HE is missing. In the present study, we combined the advantages of ultra-high field in vivo <sup>1</sup> H MRS with behavioural tests to analyse whether a long-term treatment with a multistrain probiotic mixture (VIVOMIXX) in a rat model of type C HE had a positive effect on behaviour and neurometabolic changes. We showed that the prophylactic administration of this probiotic formulation led to an increase in gut Bifidobacteria and attenuated changes in locomotor activity and neurometabolic profile in a rat model of type C HE. Both the performance in behavioural tests and the neurometabolic profile of BDL + probiotic rats were improved compared to the BDL group at week 8 post-BDL. They displayed a significantly lesser increase in brain Gln, a milder decrease in brain mIns and a smaller decrease in neurotransmitter Glu than untreated animals. The clinical implications of these findings are potentially far-reaching given that probiotics are generally safe and well-tolerated by patients.
Pubmed
Open Access
Yes
Create date
02/02/2021 15:34
Last modification date
19/02/2021 7:25
Usage data